Quantbot Technologies LP Acquires Shares of 210,079 OPKO Health, Inc. $OPK

Key Points

• Quantbot Technologies LP made a new investment in OPKO Health, Inc., purchasing 210,079 shares valued at approximately $349,000.
• CEO Phillip Frost significantly increased his stake by acquiring 675,000 shares for about $891,000, bringing his ownership to over 214 million shares.
• Equities analysts have mixed ratings on OPKO Health, with a consensus rating of "Moderate Buy" and a price target of $2.75 despite a recent earnings miss.

Quantbot Technologies LP acquired a new position in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 210,079 shares of the biotechnology company's stock, valued at approximately $349,000.

A number of other hedge funds have also recently made changes to their positions in OPK. Oak Thistle LLC purchased a new position in shares of OPKO Health during the 1st quarter worth approximately $26,000. Cerity Partners LLC purchased a new position in shares of OPKO Health during the 1st quarter worth approximately $36,000. Wealth Enhancement Advisory Services LLC boosted its position in shares of OPKO Health by 75.3% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company's stock worth $42,000 after purchasing an additional 12,417 shares during the period. Pallas Capital Advisors LLC purchased a new position in shares of OPKO Health during the 1st quarter worth approximately $43,000. Finally, Mercer Global Advisors Inc. ADV boosted its position in shares of OPKO Health by 105.6% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 43,167 shares of the biotechnology company's stock worth $63,000 after purchasing an additional 22,167 shares during the period. Hedge funds and other institutional investors own 64.63% of the company's stock.

OPKO Health Stock Down 2.8%

OPKO Health stock traded down $0.04 during trading on Monday, reaching $1.38. The stock had a trading volume of 1,663,914 shares, compared to its average volume of 2,347,663. OPKO Health, Inc. has a 52-week low of $1.11 and a 52-week high of $2.04. The business has a 50 day moving average price of $1.34 and a 200 day moving average price of $1.45. The company has a quick ratio of 3.02, a current ratio of 3.41 and a debt-to-equity ratio of 0.25. The stock has a market cap of $1.10 billion, a PE ratio of -5.52 and a beta of 1.40.

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.07). The firm had revenue of $156.80 million during the quarter, compared to analysts' expectations of $165.74 million. OPKO Health had a negative return on equity of 13.17% and a negative net margin of 26.68%.The firm's revenue was down 13.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.01) EPS. On average, analysts predict that OPKO Health, Inc. will post -0.25 EPS for the current year.

Insider Buying and Selling

In related news, CEO Phillip Md Et Al Frost purchased 675,000 shares of the company's stock in a transaction on Friday, August 8th. The shares were bought at an average cost of $1.32 per share, for a total transaction of $891,000.00. Following the completion of the purchase, the chief executive officer directly owned 214,676,448 shares of the company's stock, valued at approximately $283,372,911.36. This trade represents a 0.32% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 49.69% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on OPK shares. LADENBURG THALM/SH SH raised shares of OPKO Health to a "strong-buy" rating in a research note on Tuesday, July 8th. Wall Street Zen downgraded shares of OPKO Health from a "hold" rating to a "sell" rating in a research note on Monday, May 5th. Finally, Zacks Research raised shares of OPKO Health from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, OPKO Health has an average rating of "Moderate Buy" and an average target price of $2.75.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.